January 19, 2018 / 5:45 PM / a month ago

BRIEF-Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer

Jan 19 (Reuters) - Nucana Plc:

* NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARIN®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER

* NUCANA SAYS COMBINATION OF ACELARIN AND CISPLATIN WAS WELL-TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS AND NO DOSE-LIMITING TOXICITIES

* NUCANA PLC - IN TRIAL, 2 OF 8 PATIENTS RECEIVED ONLY ONE CYCLE OR LESS OF THERAPY DUE TO COMPLICATIONS UNRELATED TO EITHER ACELARIN OR CISPLATIN

* NUCANA SAYS PLAN TO INITIATE PIVOTAL STUDY OF ACELARIN AND CISPLATIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER IN 2018

* NUCANA PLC - ANALYSIS OF PHASE 1B STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER

* NUCANA-STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN, ACHIEVED HIGH RESPONSE RATES, WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below